Apoptotic-cell clearance is dependent on several macrophage surface molecules, including CD14. Phosphatidylserine (PS) becomes externalised during apoptosis and participates in the clearance process through its ability to bind to a novel receptor, PS-R. CD14 has the proven ability to bind phospholipids and may function as an alternative receptor for the externalised PS of apoptotic cells. Here we demonstrate that CD14 does not function preferentially as a PS receptor in apoptotic-cell clearance. Compared with phosphatidylcholine and phosphatidylethanolamine, PS was the least active phospholipid binding to human monocyte-derived macrophages and showed no specificity for soluble or membraneanchored CD14. Significantly, PS-containing liposomes failed to inhibit CD14-dependent uptake of apoptotic cells by macrophages. PS exposure was, however, found to be insufficient for either CD14-dependent or CD14-independent apoptotic-cell uptake by phagocytes. The additional features that enable apoptotic-cell clearance are derived from mechanisms that can be divorced temporally from those responsible for the morphological features of apoptosis.
Introduction
Cells undergoing apoptosis are normally efficiently phagocytosed in the absence of inflammation in vivo. The fate of apoptotic cells has important consequences for the control of immune and inflammatory responses and defective or aberrant apoptotic-cell clearance may be significant contributory factors in autoimmune disease pathogenesis. 1, 2 Although the details have not yet been worked out, the mechanisms underlying apoptotic-cell clearance appear to be highly complex involving integral phagocyte membrane receptors, apoptotic-cell surface ligands and intermediate molecules. It is well established that cell surfaces become altered as a result of apoptosis such that dying and dead cells can interact efficiently with phagocytes. Apoptosis engenders a loss of plasma-membrane phospholipid asymmetry such that the anionic phospholipid, phosphatidylserine (PS), becomes effectively exposed on the outer membrane leaflet where it functions in apoptotic-cell clearance. [3] [4] [5] Additional changes, including ill-defined alterations in surface sugars 6, 7 and in ICAM-3, 8 have also been shown to be involved in the clearance phase of the apoptosis programme, as has CD31, which was shown recently to endow viable, but not apoptotic cells, with repulsive signals affecting phagocytes. 9 Phagocytes of apoptotic cells, the most frequently studied being macrophages, possess a battery of surface molecules that can be deployed for binding and uptake of apoptotic cells. These include CD14 10 and a novel PS receptor, the PS-R, 11 together with the integrin a v b 3 , 12,13 CD36, 13, 14 the class A scavenger receptor SR-A, 15 the ATP-binding cassette transporter, ABC-1, 16 ,17 the receptor tyrosine kinase, MER 18 and the a-2-macroglobulin receptor, CD91. 19 Additional intermediate factors including thrombospondin, 13 C1q, 19, 20 Creactive protein, 21 collectins 19, 22 and calreticulin 19 may opsonise apoptotic cells or function in bridging macrophage and apoptotic-cell surfaces. The relationships between the apparently redundant clearance systems so far described have yet to be defined, although a two-signal, 'tether and tickle' mechanism has been proposed. 23 It has been shown previously that engagement of PS by the PS-R is an essential prerequisite of apoptotic-cell engulfment. 11, 23 Whether the PS-R is the only PS-receptor that is functional in the phagocytosis of apoptotic cells is unclear at present. Work from our laboratory 8, 10, 24 and elsewhere 25 has shown that human and murine macrophages utilise plasma membrane-anchored CD14 (mCD14) in apoptotic-cell clearance. In view of CD14's established capacity to interact with phospholipids, [26] [27] [28] [29] we reasoned that CD14 might function as a PS-receptor for apoptotic cells. 10 We now report, however, that CD14 does not function preferentially as a PS-receptor in apoptotic-cell clearance, supporting the PS-R's principal role in this regard. Furthermore, in the course of this work, we were able to identify apoptotic leukocytes of various lineages that exposed PS at their surfaces, displayed classical morphological features of apoptosis, and yet were unable to interact efficiently with monocyte-derived macrophages in vitro. These apoptotic cells subsequently acquired, through cell-autonomous means, additional features that enabled their binding and phagocytosis through both CD14-dependent and -independent mechanisms.
These results demonstrate firstly that PS is an unlikely candidate ligand of apoptotic cells for mCD14, and secondly that externalisation of PS is insufficient for apoptotic-cell clearance by human monocyte-derived macrophages (HMDM) in vitro. While identification of the additional features of apoptotic cells that are required for efficient phagocytosis is beyond the scope of the present investigations, it can be concluded that they are generated through biochemical mechanisms that can be uncoupled, at least temporally, from those responsible for the stereotypical morphological features of apoptosis.
Results
PS exposure and capacity for CD14-dependent clearance are common features of apoptotic cells that are not consistently related
In previous studies, we have demonstrated the involvement of macrophage CD14 in the clearance of apoptotic lymphocytes, neutrophils and embryonic kidney cells by HMDM. 8, 10, 24 The results shown in Figure 1 confirm and extend these observations. Using the CD14-blocking mAb 61D3, we demonstrate that macrophage clearance of different lineages of apoptotic cells of human, murine and simian origin is dependent, to varying extents, on CD14 (Figure 1a ). When annexin V was used to label the same panel of apoptosis-induced cells it was found that PS was exposed in all cases, but to varying degrees ( Figure 1b) . Furthermore, we found no consistent correlation between the amount of annexin-V labelling and the capacity to interact with HMDM. For example, apoptotic (staurosporineinduced) Jurkat T cells were labelled substantially by annexin V, but only displayed low-level capacity to interact with macrophages (22% for the cells shown (Figure 1b) . By contrast, staurosporine-induced apoptotic A1.1 cells -which also labelled well with annexin V though to a lesser extent than Jurkats in the samples analysed (Figure 1b) -were able to interact significantly better with HMDM (79%, Figure 1b) . Therefore, while PS externalisation is a prominent and consistent feature of apoptosis that is paralleled by macrophage clearance, the degree of annexin-V labelling of an apoptotic cell appears not to be directly coupled to its capacity to be engulfed by HMDM.
PS-containing liposomes fail to bind preferentially to HMDM, or to cell-bound or soluble recombinant CD14
In order to test the hypothesis that CD14 acts as a receptor for PS displayed on apoptotic cells, radiolabelled liposomes composed either of PC alone or in combination with PS (50 : 50) or PE (50 : 50) were assessed for their ability to bind to HMDM, or to recombinant plasma membrane-anchored or soluble CD14. Such PS-containing liposomes have been used previously to define the function of PS in apoptotic-cell phagocytosis. 3, 35 As shown in Figure 2a , while all liposome preparations bound very poorly to HMDM, PC liposomes always bound most effectively, while PS-containing liposomes bound least. When recombinant CD14 expressed on BJAB cells was analysed in the same way, no differences were demonstrable between CD14-negative and CD14-positive cells with any of the liposomes tested (Figure 2b ), although PS-containing liposomes were more active than the PC-only and PE preparations. Similarly, when recombinant soluble CD14 (CD14-Fc) was compared with a control Fc fusion protein (ICAM-3-Fc), no significant specific binding to CD14 was observed with any of the liposome preparations (Figure 2c) , although, again, PS-containing liposomes were the most active in binding. These results indicate that while CD14 can bind liposomes including those containing PS, it does so no more effectively than other receptors, including ICAM-3.
CD14-dependent macrophage clearance of apoptotic cells can occur in the presence of PS-containing liposomes that are active in inhibiting PS-dependent apoptotic-cell clearance
The activity of PS-receptors in the clearance process was defined originally as the specific inhibition of the engulfment of apoptotic cells by PS-containing liposomes that compete for PSreceptors. 3, 35 We used this approach to assess the activity of PS-receptors in clearance of apoptotic lymphocytes by HMDM. As shown in Figure 3 , HMDM that interacted with apoptotic cells via CD14-dependent means (as judged by inhibition with 61D3 mAb) were not inhibited by PS-containing liposomes. The biological effectiveness of the liposome preparations was monitored using macrophages treated with b-glucan ( Figure 3 ). Such macrophages were inhibited in their capacity to interact with apoptotic lymphocytes both by 61D3 and by PS-containing liposomes, though not by PC-only or PE-containing liposomes ( Figure 3 ). These results indicate that, at least in the case of non-activated HMDM, CD14 is functional in apoptotic-cell clearance in the absence of demonstrable PS-receptor activity.
Lipid-symmetric erythrocytes fail to affect apoptotic-cell clearance by monocyte-derived macrophages
To investigate further the possible activity of PS-receptors in engulfment of apoptotic lymphocytes by HMDM, we assessed whether lipid-symmetric erythrocytes were able to inhibit the process. We reasoned that more sensitive definition of the activity of PS-receptors might be achieved through competition by PS exposed in a plasma-membrane context. As shown in Figure 4 , lipid-symmetric erythrocytes failed to affect the interaction of apoptotic lymphocytes with HMDM ( Figure 4a ). Again, inhibition by 61D3 confirmed that the CD14-dependent pathway was active in these assays. Staining with annexin V was used to monitor the externalised PS of the lipid-symmetric erythrocytes. These results provide further evidence that HMDM engage in CD14-dependent apoptotic-cell clearance in the absence of demonstrable PS-receptor activity.
PS exposure is insufficient for clearance of apoptotic leukocytes by human macrophages in vitro
To define further the relationship between PS exposure and CD14-dependent clearance of apoptotic cells by human macrophages, the abilities of populations of human leukocytes (1) to expose PS and (2) to interact with macrophages were assessed in parallel over time following treatment with apoptosis-inducing stimuli. As shown in Figure 5 , PMNs were followed for a period of 12 h after induction of apoptosis using a single dose of UV radiation (200 mJ cm À2 ). Flow cytometric ification of PS such that annexin-V binding was inhibited. Figure 6b shows the results of the same cells interacting with HMDM over the same time-course and indicates clear increases of interaction with induction time. Substantial CD14 dependence of all interactions was observed after 5 hours' induction. Between 2 and 5 hours' induction, the proportion of macrophages interacting with apoptotic BL cells had increased by only 10% (Figure 6b ), while the proportion of annexin-V binding cells had increased by almost 40% ( Figure  6a ). By contrast, a further 12% increase in interacting macrophages between 5 and 8 hours' induction reflected approximately a 10% increase in annexin-V binding whereas another 12% increase in interacting macrophages between 8 and 24 h was paralleled by a decrease in overall annexin-V binding to the apoptotic cells. Phagocytic Index was used to monitor more closely the engulfment of apoptotic BL cells over time since it accounts for the number of engulfed cells per macrophage as well as the proportion of macrophages engulfing apoptotic cells. However, as shown in Figure 6c , Phagocytic Index also failed to correlate closely with annexin-V binding to the target cells. Significantly, the highest Phagocytic Index (102, Figure 6c ) was observed using 24-h cells, whereas cells at 8 h -the peak of annexin-V bindingproduced a Phagocytic Index by HMDM of only 45. Morphological characteristics of apoptosis can be acquired prior to features that permit efficient phagocytosis of apoptotic cells in vitro
In the three systems tested above, apoptosis was monitored in the target leukocytes by fluorescence microscopy of nuclear morphology following DAPI staining (Figure 5c , d, 6d, e and 7c, d). These morphological analyses yielded an unexpected result: that major populations of classically apoptotic cells could be identified that were clearly unable to interact effectively with macrophages. Thus, as shown in Figure 5 , even though a large proportion of the PMNs were apoptotic at 4 and 7 h after induction (Figure 5c, d ), few were engulfed by HMDMs at these times (Figure 5b) . Similarly, as shown in Figure 6 , interaction of BL cells with HMDM was relatively inefficient at 5 h after induction of apoptosis ( Figure  6b , c) even though at this time almost 70% of the cells were morphologically apoptotic (Figure 6d) . By 8 h, the cells were maximally apoptotic by morphological criteria (Figure 6d ), but were only recognised efficiently at 24 h (Figure 6b, c) . Similar observations were made with K562, which approached maximum levels of morphological apoptosis by 8 h after induction by TRAIL (Figure 7c, d) . At this time only low levels of interaction with THP-1 phagocytes could be measured (Figure 7b ).
Without exception, continued culture of apoptotic cells resulted in their acquisition of additional features that enabled more efficient interaction with macrophages ( Figure 5b, 6b, c,  7b) . The capacity to interact with macrophages was acquired with the same kinetics as loss of plasma-membrane integrity (Figure 5a, b, 6a-c, 7a, b) . This suggests that the capacity of apoptotic cells to be engulfed in the present assays is gained at a relatively late stage in the apoptosis programme. Furthermore, the results show that the molecular mechanisms responsible not only for the exposure of PS, but also for the nuclear morphological features of apoptosis are insufficient to enable macrophage engulfment.
Discussion
The present work was initiated to clarify possible relationships between CD14-and PS-dependent apoptotic-cell clearance mechanisms. Growing evidence that CD14, an established macrophage receptor of apoptotic cells, 10, 25 can bind PS, a plasma-membrane phospholipid that becomes externalised during apoptosis, 3 provided an important impetus for these investigations. While the work that established CD14 as a phospholipid receptor (and indeed phospholipid transfer protein) used the soluble form of CD14 (sCD14), 26 which has yet to be proven active in apoptotic-cell clearance, it is now known that both sCD14 and mCD14 can bind phospholipids, including PS. [27] [28] [29] We analysed the selectivity of binding of PS-containing liposomes to sCD14 or mCD14. We also investigated the function of mCD14 on macrophages (human monocyte-derived, HMDM), which have been reported previously to engulf apoptotic cells via mechanisms that are not preferentially biased towards the activity of receptors for PS as assessed by the inhibitory effects of PScontaining liposomes. 35 We found that many different cell types engaged in apoptosis triggered by a variety of stimuli could interact with HMDM through CD14-dependent means. The involvement of CD14, however, did not correlate closely with the levels of PS exposed (annexin-V positivity, Figure 1) . Liposome-binding studies revealed that, while PS can undoubtedly bind BJAB transfectants overexpressing mCD14 and soluble CD14-Fc, this binding is not CD14-specific since PS-containing liposomes also bound with comparable efficiency both to CD14-negative cells and to ICAM-3-Fc (Figure 2 ). It remains possible that PS-containing liposomes bind effectively both to CD14 and to ICAM-3 (since BJAB cells express ICAM-3 -not shown). Since both molecules have been implicated in apoptotic-leukocyte clearance by HMDM -CD14 on the macrophage and ICAM-3 on the apoptotic cell 8 -it is conceivable that bodies on which PS is exposed (e.g. apoptotic-cell blebs) could physically bridge apoptotic cells and macrophages, thereby allowing CD14 to function as a PS-receptor.
Significantly, PS-containing liposomes were unable to inhibit apoptotic-cell clearance by HMDM under conditions in which CD14 was active, as judged by anti-CD14 mAb inhibition (Figure 3 ). Taken together, these results indicate that CD14 is unlikely to bind preferentially to apoptotic-cellassociated PS and fails to function as a PS-receptor on HMDMs. It remains theoretically possible that mCD14 is active as a PS-receptor on b-glucan-treated HMDMs since these macrophages have demonstrable PS-receptor activity, as judged by the capacity of PS liposomes to inhibit apoptoticcell engulfment 33 ( Figure 3 ). It is also conceivable that CD14 could function as a PS-R of nonactivated HMDM that required access to PS in a more physiological context than that of PSloaded liposomes. This seems improbable, given the inability of lipid-symmetric erythrocytes, which display PS in the context of a plasma membrane, to inhibit apoptotic-cell clearance by HMDM (Figure 4) .
The results presented here argue strongly that mCD14 does not share functional activity with the PS-R that has been elegantly described by Fadok et al. 11 in binding PS to effect apoptotic-cell engulfment. It remains a possibility that other phospholipids are active as CD14 ligands, especially since PS has a relatively low affinity among phospholipids for CD14.
27,29 CD14, however, has the known ability to interact with a wide range of biologically active molecules encompassing lipids, proteins and carbohydrates, [36] [37] [38] and may prove to engage a diverse range of ligands in order to mediate apoptotic-cell clearance. The elucidation of such CD14 ligand(s) will be crucial in furthering current understanding of CD14's role in the removal of apoptotic cells.
A constructive model of apoptotic-cell clearance has recently been proposed in which two signals, 'tether and tickle' are required for the full biological response of the phagocyte towards the apoptotic cell: engulfment accompanied by anti-inflammatory signal transduction. 23 The evidence to date suggests that a multitude of molecules, including CD14, function in tethering apoptotic cells to phagocytes (signal one) and that a second signal is provided by PS interacting with the PS-R. 23 Our results from the present as well as previous studies 10 are consistent with the view that CD14 serves a tethering function in interacting with apoptotic cells. We were intrigued, however, by our findings (Figures 5-7 ) that apoptotic cells appear to acquire the capacity to interact with HMDM -through CD14-independent as well as CD14-dependent mechanisms -at a relatively late stage in the apoptotic process, hours after exposure of PS and the acquisition of apoptotic nuclear features. These observations were made in three different target cell types, two different apoptosis stimuli and two different human macrophage sources -primary HMDM and differentiated THP-1 cells. This would suggest that the capacity of apoptotic cells to interact with human macrophages can generally be uncoupled, at least temporally, from the mechanisms governing PS-exposure and morphological change during apoptosis. These results are in accordance with published work indicating that the stereotypical morphological features of the apoptotic nucleus derive from caspase-3 activation, whereas PS exposure results from mechanisms that are independent of caspase-3.
39-42
Whether the PS-R described by Fadok et al. 11 is functional in the engulfment of unstimulated HMDM is not yet clear. These phagocytes express only low levels of PS-R and activity of this receptor in apoptotic-cell clearance by HMDM cannot be demonstrated using either PS-containing liposomes 35 ( Figure 3 ) or anti-PS-R mAb blockade. 11 However, it has been shown that engulfment of anti-CD36-tethered erythrocytes by HMDM can be induced by PS and inhibited by anti-PS-R mAb, 23 indicating that unstimulated HMDM do indeed have functional PS-R. The data presented here are consistent with the view that PS-R, rather than CD14, is the most likely PS-receptor of apoptotic cells on HMDM.
Current evidence indicates that PS exposure is a necessary prerequisite to the efficient engulfment of apoptotic cells both by amateur and by professional phagocytes. 5, 43 Some studies have implied that PS exposure may also be sufficient for apoptotic-cell engulfment, 5, 44, 45 and indeed it has been concluded that any additional features of apoptotic-cell membranes that may be required for engulfment become available immediately following PS externalisation. 45 Artificial 'loading' of viable-cell surfaces with PS using PS-containing liposomes or N-ethylmaleimide treatment has shown that the capacity of cells to be phagocytosed either by murine macrophages 5, 44 or by fibroblasts 5 can be uncoupled from apoptosis. However, efficiencies of phagocytosis were relatively low in these studies and the mode of manipulation of the cells could have generated additional surface changes. Thus, it is unlikely that the effects of N-ethylmaleimide treatment are limited to phospholipids and PS loading may incur additional alterations in membrane conformation that are required for engulfment. In addition, different populations of phagocytes may have different requirements of the apoptotic-cell membrane. Our results showing that features subsequent to PS exposure are required for efficient binding and phagocytosis of apoptotic cells support the contention that while PS exposure may be necessary for apoptotic-cell clearance, it is not sufficient. Indeed, PS itself may require modification in order to perform effectively at the apoptotic-cell surface. 46 The requirement for specific additional features of dying cells would militate against inappropriate engulfment of cells -B lymphocytes for example 47 -that expose PS for reasons unrelated to cell death. Further studies will be required to determine to what extent the defined additional features of dying cells are required by non-macrophage phagocytes such as 'amateur' phagocytic neighbours in solid tissues and immature dendritic cells.
It will be important to identify, in molecular terms, the additional features that must be acquired by apoptotic cells to enable their efficient phagocytosis by HMDM (and other phagocytes, as appropriate). Phospholipids apart, little is known about cell-surface changes that occur as a consequence of apoptosis, although changes in cell-surface carbohydrates 48, 49 and modification of ICAM-3 8 are known to occur at apoptotic-cell surfaces and to contribute to phagocytic clearance. The antigen identified by the PH2 antibody is also involved in the clearance of late apoptotic cells. 50 Furthermore, oxidation of molecules other than PS may be required to enhance apoptotic-cell clearance. 51 It has also been shown recently that loss of repulsive mechanisms involving CD31 are required for interactions between apoptotic cells and phagocytes. 9 While we have not sought in the present studies to identify definitive cell-surface characteristics that allow HMDM to interact efficiently with apoptotic cells, our results demonstrate that the cell-autonomous changes (Figures 5b, 6b, 7b ) to permit clearance under serum-free conditions occur late in the apoptosis programme. These changes coincide, in our hands, with events that lead to plasma-membrane disruption, as measured by inclusion of propidium iodide (Figures 5a, 6a, 7a ) though less marked differences between the uptake of early and late apoptotic neutrophils by HMDM have been reported recently. 52 We did not address the question of whether the HMDM assay selectively measures the uptake of intact, late-apoptotic or of secondarily necrotic (leaky apoptotic) cells, or both populations. Whatever the case, we conclude that the ability of HMDM to undertake apoptotic-cell clearance under serumfree conditions is focussed on mechanisms that selectively target late-apoptotic or secondarily necrotic cells. These may be either CD14-dependent or CD14-independent mechanisms. More importantly, our results suggest that mechanisms that are thought to operate effectively in vivo to remove apoptotic cells at early stages in the programme are nonfunctional under the conditions studied. An obvious possibility is that established mechanisms that enhance apoptotic-cell clearance through plasma-borne factors such as collectins and C1q by HMDM 19 selectively enhance the engulfment of early stage apoptotic cells. Clearly, any role for plasma-borne factors may be relevant in vivo only to the clearance of dying cells in the circulation if such factors are absent from solid tissue sites. We are currently pursuing the role of exogenous soluble factors in enhancing the uptake of such cells by CD14-dependent means. Given the capacity of cells to repel phagocytes in order to avoid engulfment 9 it will also be important to determine within the current models precisely when that repulsive activity is lost.
In conclusion, these studies demonstrate that PS (1) is unlikely to function as a major CD14 ligand in apoptotic-cell clearance, and (2) is wholly insufficient for apoptotic-cell clearance by human macrophages displaying active CD14-dependent, as well as CD14-independent clearance capabilities. As yet, there is no evidence that apoptotic-cell engulfment can proceed in the absence of PS exposure. The results presented here are consistent with the view that loss of plasma-membrane asymmetry during apoptosis may serve at least two functions. One is exposure of PS, which permits ligation of PS-receptors on phagocytes, notably PSreceptor. Another is to provide the appropriate plasmamembrane context for additional changes that are required for efficient phagocytosis and that involve other phagocyte receptors, including CD14. Finally, our results also indicate that assessment of apoptotic-cell clearance in vitro may often be focussed on relatively late events that occur well beyond PS exposure and after the morphological hallmarks of apoptosis. The late-phase apoptotic-cell clearance pathways described here are likely to be represented among several others that cooperate to ensure the normally efficient phagocytosis of cells undergoing apoptosis in vivo.
Materials and Methods

Cell isolation, cell lines and culture
Peripheral blood PMN were isolated from citrated blood from normal volunteers by dextran sedimentation and centrifugation on Percoll as described. 30 Monocytes were isolated from defibrinated blood 24 and cultured for 7 days in IMDM (Invitrogen Corp., Paisley, UK) containing 10% autologous serum on glass slides or multiwell plates as described previously. 10, 19 Mutu I Burkitt's lymphoma (BL) cells, 31 BJAB (human B), K562 (human erythroleukaemia), Jurkat (human T), THP-1 (human myelomonocytic), U937 (human myelomonocytic) and A1.1 (murine T), cells were cultured continuously in RPMI 1640 medium containing 2 mM Lglutamine supplemented with 10% Serum Supreme (BioWhittaker, Wokingham, UK), 100 IU/ml penicillin and 100 mg/ml streptomycin. HeLa 229 (human epithelial) and COS-1 (simian epithelial) cells were cultured similarly, but in DMEM (Invitrogen Corp., Paisley, UK). CD14-expressing BJAB cells were prepared by transfection by electroporation of pEFMC1neopA 32 containing human CD14 followed by selection using G418. Control transfectants were prepared using pEFMC1neopA with CD14 in reverse orientation. CD14 expression was monitored by immunofluorescence staining using the anti-CD14 mAb 63D3 followed by flow cytometric analysis.
Apoptosis induction and quantification
PMN or BL cells were subjected to UV-B irradiation to induce apoptosis. BL cells resuspended in RPMI containing 10% Serum Supreme received 100 mJ/cm 2 ; PMN were resuspended in 0.2% BSA/RPMI 1640, exposed to UV-B (200 mJ/cm 2 ) and subsequently rotated at 371C for the indicated times. BL cells were also induced using ionomycin (Sigma, 1 mg/ml, 18 h) as described. 24 K562 cells in RPMI containing 10% Serum Supreme were induced to undergo apoptosis with TRAIL (BioMol, Plymouth Meeting, PA, USA, 125 ng/ml) in the presence of cycloheximide (Sigma, Poole, UK, 10 mg/ml). Apoptosis was induced in other cells using either etoposide (Sigma, 100-850 mM) or staurosporine (Sigma, 1 mM) as indicated. For analysis of apoptotic nuclear morphology, cells were fixed in 1% formaldehyde, stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma, 250 ng/ml) and observed using a Zeiss Axioskop 2 fluorescence microscope (Carl Zeiss Ltd., Welwyn Garden City, UK). For quantitative analyses, percentages of apoptotic cells per X200 macrophages counted per sample were enumerated. 
Annexin-V labelling and flow cytometry
Assays of macrophage interaction with apoptotic cells
Assay of interaction (binding and phagocytosis) of HMDM with apoptotic cells was carried out either on multiwell glass slides 10 or in 24-well plates 19 as described. Briefly, for the slide-based assay, macrophages and apoptotic cells (10 6 per well) were co-cultured for 1 h at 371C in RPMI containing 0.2% (w/v) bovine serum albumin (Sigma). Unbound cells were removed by extensive washing and slides were fixed in methanol, stained with Jenner/Giemsa (BDH) and mounted in DePeX (BDH) prior to examination by light microscopy. Assays were performed similarly in 24-well plates, but at the end of the procedure, cells were fixed in 1% formaldehyde and stained with Diff-Quik II (Dade Diagnostika Gmbh, D-80807 Munich). In all cases, at least 200 macrophages were assessed in each of the duplicate wells. As appropriate, anti-CD14 mAbs 61D3 and 63D3 were included at a 1 : 100 dilution of ascitic fluid, liposomes were added (10% v/v) and erythrocytes were included at 10 7 per slide well. For some experiments, macrophages were treated with b-glucan (25 mg/ml À1 , Sigma) for 48 h prior to the assay. Data are presented either as percent macrophages interacting with apoptotic cells or as Phagocytic Index calculated as the percentage of phagocytosing macrophages Â the average number of apoptotic cells engulfed per macrophage. 33 For some experiments, THP-1 cells were used as the macrophage source. Cells were labelled using the fluorescent dye PKH26 (Sigma, 4 mM) for 5 min, washed 3 times and cultured for 72 h in the presence of dihydroxy-1 Vitamin D 3 (a kind gift from Dr. Lise Binderup, Leo Pharmaceuticals, Ballerup, Denmark, 100 nM) and TPA (Sigma, 250 nM) in 48-well plates. Target K562 cells were labelled with Cell Tracker green (CMFDA, Molecular Probes, Eugene, OR, USA, 1 mM, 15 min), washed 3 times and then induced to undergo apoptosis. THP-1 interaction was carried out in serum-free conditions as described for HMDM assays above. Induced K562 cells (5 Â 10 5 ) were added to each well of THP-1 cells in 400 ml. After 1 h at 371C, wells were washed once to remove the majority of unbound cells and 200 ml warmed trypsin/EDTA solution (Invitrogen) added. Cold RPMI containing 10% Serum Supreme (300 ml) was subsequently added and cells were lifted into suspension by gentle pipetting. Analyses were carried out on the flow cytometer. THP-1 cells, gated according to light-scatter properties and red PKH26 fluorescence, were assessed for CMFDA (K562) fluorescence and results expressed as THP-1 cells interacting with K562 (%).
Liposome preparation and binding
Liposomes were prepared according to established methods. L-aphosphatidyl-L-serine (Sigma) or L-a-phosphatidylethanolamine (Sigma), or mixed in varying proportions with L-a-phosphatidylcholine (Sigma) in chloroform at 0.1 mM. Following evaporation of solvent under nitrogen, liposomes were formed in RPMI 1640 medium using a sonicating bath (Decon, Ultrasonic Ltd). The liposomes were vortex mixed and left at room temperature for 2 h before use. Radiolabelled liposomes were prepared by incorporation of L-3-Phosphatidyl (N-methyl 3 H) choline 1,2 dipalmitoyl (5 mCi/ml, Amersham, Life Science) prior to solvent extraction. Binding of radiolabelled liposomes to HMDM or BJAB cells was assessed after incubation for 60 min at 371C and extensive washing with PBS. Cells were lysed in 200 ml PBS containing 2% SDS and 100 ml aliquots were subjected to liquid scintillation counting. Binding of liposomes to soluble recombinant CD14 was carried out in 96-well ELISA plates. Results of cell and protein binding assays are expressed as % input radiolabel calculated as: (DPM of extract total/DPM of input liposomes) Â 100.
Preparation of lipid-symmetric erythrocytes
The method used was modified from Schlegel and Rechsteiner. 34 Erythrocytes from heparinised blood were washed 5 times with 0.15 M saline and resuspended in an equal volume of Hanks' balanced salts solution (HBSS; Life Technologies). To swell the erythrocytes, 200 ml of the suspension was added to a hypotonic buffer made up of 5 ml of distilled water and 6 ml of HBSS. The suspension was then centrifuged at 51C to produce a pellet of swollen erythrocytes. The supernatant was removed and 800 ml of 10 mM Tris, pH 7.4 containing 1 mM CaCl 2 was added to the pellet with gentle mixing, allowing the erythrocytes to be loaded with Ca
2+
. The erythrocytes were then placed on ice for 4 min after which time 60 ml of HBSS (10 Â concentration) was added with vortex mixing to shrink the cells. Following this the erythrocytes were incubated at 371C in a water bath for 60 min and then gently washed twice in HBSS.
